Related Experiment Videos
Metformin monotherapy for type 2 diabetes mellitus
A Saenz1, I Fernandez-Esteban, A Mataix
1Centro de Salud Pozuelo 1, INSALUD - Madrid, Emisora s/n, Pozuelo de Alarcón, Madrid, Spain, 28224. antoniosaenz@ya.com
The Cochrane Database of Systematic Reviews
|July 22, 2005
Summary
Metformin monotherapy offers significant benefits for type 2 diabetes patients, improving glycaemic control, weight, and lipids. It may prevent vascular complications and mortality, especially in overweight or obese individuals.
Area of Science:
- Endocrinology
- Pharmacology
- Clinical Medicine
Background:
- Metformin is a primary anti-hyperglycaemic agent for type 2 diabetes mellitus.
- Type 2 diabetes is associated with microvascular and macrovascular complications.
- Previous meta-analyses focused only on secondary outcomes.
Purpose of the Study:
- To evaluate metformin monotherapy's effects on mortality, morbidity, quality of life, and metabolic parameters in type 2 diabetes.
- To compare metformin's efficacy against other oral antidiabetic agents and placebo.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials.
- Searched multiple electronic databases and reference lists up to September 2003.
- Included trials comparing metformin with other oral interventions for type 2 diabetes.
Main Results:
- Analyzed 29 trials (5259 participants), comparing metformin with sulphonylureas, placebo, diet, thiazolidinediones, insulin, meglitinides, and glucosidase inhibitors.
- Metformin showed significant benefits in glycaemic control, weight, dyslipidaemia, and diastolic blood pressure.
- Obese patients on metformin experienced greater benefits in diabetes-related outcomes and all-cause mortality compared to other treatments.
Conclusions:
- Metformin is a potential first-line therapy for overweight/obese type 2 diabetes patients, potentially preventing vascular complications and mortality.
- Metformin demonstrates significant improvements in glycaemic control and moderate benefits in weight, lipids, and blood pressure.
- Other antidiabetic agents showed no superior benefits over metformin for glycaemic control, weight, or lipids.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...